All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
BMT Tandem Meetings | Infliximab with or without extracorporeal photopheresis for steroid-refractory acute GvHD
Data from a single-center, retrospective analysis of patients with for steroid-refractory acute graft-versus-host disease (SR-aGvHD), led by Marietta Nygaard of Rigshospitalet Copenhagen University Hospital was presented Wednesday February 21 at the 2018 BMT Tandem Meetings in Salt Lake City, Utah. The study analyzed 17 years (2000 to 2017) of inflixmab patient outcomes compared with 5 years (2013 to 2017) of extracorporeal photopheresis (ECP) added to infliximab.
Key findings:
- N = 103 total patients
- N = 67 infliximab only
- N = 36 infliximab + ECP
- Baseline differences in treatment groups
- More matched unrelated donors in ECP group, P = 0.008
- More GI GvHD in infliximab group, P = 0.00
- More skin GvHD in ECP group, P = 0.01
- Lower dose of prednisone equivalent in ECP group, P = 0.001
- Freedom from treatment failure at 6 months
- Infliximab = 35.8%
- Infliximab + ECP = 44.4%
- Trend toward better 5-year overall survival in ECP group, P = 0.088
This small, single center analysis suggests improvement in outcomes for SR-aGvHD by using combination therapy of infliximab and ECP. Larger, prospective trials should be initiated to validate the clinical trends observed in this study.
References
Your opinion matters
When would you be most likely to consider prescribing belumosudil third-line and beyond?